[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-chronic-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-chronic-liver-disease":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,38,65,90,113,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100530025","lsm-and-ssm-for-the-diagnosis-of-csph-a-prospective-cohort-study-100530025",false,"NCT06181409","LSM and SSM for the Diagnosis of CSPH: a Prospective Cohort Study","Diagnosing and Monitoring Portal Hypertension Non-invasively Using Spleen Stiffness Measurement in Patients With Advanced Chronic Liver Disease: a Prospective Cohort Study","Inclusion Criteria:\n\n* Age above 18years old\n* Advanced chronic liver disease (defined as LSM ≥ 10kPa)\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Transjugular intrahepatic portosystemic shunt\n* previous liver transplantation\n* Abnormality of the porto-mesenteric system (portal vein thrombosis, splenic vein thrombosis, splenectomy, portal cavernomatous transformation, porto-caval shunts)\n* Hematological malignancy","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to assess non-invasive tools' efficacy in predicting portal hypertension-related complications in individuals with advanced chronic liver disease. The main question it aims to answer are:\n\n\\- what are the cut-off values for non-invasive tests (NITs) (including LSM, SSM) that predict the presence and occurrence of hepatic decompensation in individuals with advanced chronic liver disease?\n\nParticipants will undergo regular study visits involving non-invasive tests (LSM, SSM) and assessments to monitor hepatic decompensation over the study period.",[24],"Advanced Chronic Liver Disease","RECRUITING","2026-03-10",{"date":28,"type":29},"2026-03-12","ACTUAL",{"date":31,"type":29},"2024-01-10",{"date":33,"type":20},"2028-12",{"name":35,"class":36},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":52,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":37},"100475752","3d-mre-for-assessing-cirrhosis-advanced-chronic-liver-disease-and-portal-hypertension-100475752","NCT05475015","3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension","Three-dimensional MR Elastography for Assessing Cirrhosis and Portal Hypertension (CHESS2206): A Prospective Multicenter Study","Inclusion criteria were: (1) ≥18 years; (2) written informed consent; (3) confirmed ACLD of any liver disease etiology; (4) clinically indicated for HVPG measurement, with 3D-MRE performed within one month prior.\n\nExclusion criteria were: (1) hepatic or extrahepatic malignancies, or large hepatic or splenic focal diseases affecting MRE measurement; (2) MR or HVPG contraindications; (3) prior liver or splenic surgery affecting MRE measurement; (4) treatment with nonselective β-blockers (NSBB) between MRE and HVPG measurements; (5) invalid or unreliable HVPG or MRE results and (6) biliary obstruction or dilation on MR images.","75 Years",{"count":47,"type":20},150,"How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis or advanced chronic liver disease. We plan to investigate the ability of three demensional-magnetic resonance elastography (3D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis or advanced chronic liver disease.",[50,51,24],"Cirrhosis, Liver","Portal Hypertension",[53,54,55],"3D-MRE","HVPG","advanced chronic liver disease","2026-02-05",{"date":58,"type":29},"2026-02-09",{"date":60,"type":29},"2022-08-16",{"date":62,"type":20},"2026-12-01",{"name":64,"class":36},"Shengjing Hospital",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":75,"studyType":21,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":37},"100556323","prediction-of-decompensation-and-hcc-development-in-advanced-chronic-liver-disease-100556323","NCT06523608","Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease","Prediction of Decompensation and HCC Development in Patients With Advanced Chronic Liver Disease by the PLEASE and M10S20 Algorithms","DETECT","Inclusion Criteria:\n\n* The patient admitted\u002Freferred to study center is hospitalized or is an outpatient with advanced chronic liver disease (based on the BAVENO criteria)\n\nExclusion Criteria:\n\n* Pregnancy\n* Age \\\u003C18\n* Evidence of current malignancy except for non-melanocytic skin cancer\n* Presence or history of severe extra-hepatic diseases (e.g., chronic renal failure requiring hemodialysis, severe heart disease (New York Heart Association (NYHA) \\> II); severe chronic pulmonary disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD) \\> III), severe neurological and psychiatric disorders).\n* Human Immunodeficiency Virus (HIV) positive patients.\n* Previous liver or other transplantation.\n* Patients who decline to participate or who cannot provide prior written informed consent and when there is documented evidence that the patient has no legal surrogate decision maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent.\n* Physician's denial (e.g. the investigator considers that the patient will not follow the protocol scheduled).",{"count":74,"type":20},600,"2 Years","The aim of this observational study is to predict the short- and long-term development of acute severe disease events, de novo hepatocarcinoma (HCC) and mortality in patients with advanced chronic liver disease using the M10S20 (Liver stiffness and Model for End-Stage Liver Disease Score \\[MELD\\] combined) and PLEASE (Platelet, Etiology, Age, Sex und Elastography) scores, as well as the validation of the cost-effectiveness of the algorithm.\n\nPatients in this study are randomly divided into two groups:\n\n* Control group: patients are examined according to the current clinical standard protocol (biannual follow-up).\n* Stratified surveillance program:\n\n  * High-risk patients will receive an appointment for a hospital visit every 3 months.\n  * Low-risk patients could receive an appointment in one year. When necessary, if decompensation develops or HCC occurs, patients could be followed-up more frequently.",[78,79,80,24],"Liver Diseases","Hepatocellular Carcinoma","Hepatocarcinoma","2025-12-15",{"date":83,"type":29},"2025-12-22",{"date":85,"type":29},"2024-09-01",{"date":87,"type":20},"2027-09",{"name":89,"class":36},"University Hospital Muenster",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":99,"studyType":21,"phases":4,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":37},"100596196","natural-history-of-advanced-chronic-liver-diseases-100596196","NCT07042308","Natural History of Advanced Chronic Liver Diseases","Natural History of Advanced Chronic Liver Diseases and Factors Associated With Hepatic Events - a Registry Study","Inclusion Criteria:\n\n* Aged 18 or above\n* Known ACLD, defined by:\n\n  * LSM \\> 10kPa or\n  * Clinical cirrhosis, suggested by 1. ultrasonography of the hepatobiliary system shows features of cirrhosis (e.g. shrunken and nodular liver) and portal hypertension (e.g. dilated portal vein, portal-systemic collaterals or varices, splenomegaly, ascites). 2. Oesophagogastroduodenoscopy (OGD) shows presence of oesophageal varices (OV) and\u002For gastric varices (GV) and\u002For portal hypertensive gastropathy.\n\nExclusion Criteria:\n\n* Current or past history of hepatocellular carcinoma (HCC)\n* History of liver transplantation\n* Asplenism or history of splenectomy\n* Serious medical illness with limited life expectancy of less than 6 months\n* Pregnancy\n* Unable to obtain or refusal of informed consent from patient",{"count":98,"type":20},500,"10 Years","This is a retrospective-prospective registry cohort study. Patients with advanced chronic liver disease (ACLD) will be prospectively invited to this study. The study follow-up duration will be 10 years. The primary outcome is incident hepatic events and liver-related mortality. Participants will undergo annual transient elastography examination.",[102,24],"Cirrhosis",[55],"2025-06-25",{"date":106,"type":29},"2025-06-29",{"date":108,"type":29},"2024-09-25",{"date":110,"type":20},"2035-12",{"name":112,"class":36},"Chinese University of Hong Kong",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":37},"100550612","phase-4-non-selective-beta-blocker-in-compensated-advanced-chronic-liver-disease-100550612","NCT06449339","Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease","Baveno VII Criteria-guided Initiation of Non-selective Beta Blocker in Patients With Compensated Advanced Chronic Liver Disease to Reduce Hepatic Decompensation: an Open-label Randomised Controlled Trial","BB_cACLD","Inclusion Criteria:\n\n* Aged 18 years of above\n* Established diagnosis of chronic liver disease(s) of the following etiologies\n\n  * Alcohol-related liver disease (ARLD)\n  * Chronic hepatitis B (CHB)\n  * Chronic hepatitis C (CHC)\n  * Metabolic dysfunction-associated steatotic liver disease (MASLD) § Non-obese (BMI \\\u003C30kg\u002Fm2) and obese (BMI ≥30 kg\u002Fm2)\n* In high-risk grey zone or CSPH, by Baveno VII criteria (for ARLD, CHB, CHC and non-obese MASLD) or ANTICIPATE-NASH model (for obese MASLD) within 6 months from screening\n\n  * Baveno VII criteria (for ARLD, CHB, CHC and non-obese MASLD)\n\n    * LSM ≥25 kPa (CSPH)\n    * LSM ≥20 kPa - \\\u003C25 kPa and platelet count \\\u003C150 x 10\\^9\u002FL; or LSM ≥15 kPa - \\\u003C20 kPa and platelet count \\\u003C110 x 10\\^9\u002FL (high-risk grey zone)\n  * ANTICIPATE-NASH model (for obese MASLD)\n\n    * Predictive probability for CSPH \\>90% (CSPH)\n    * Predictive probability for CSPH ≥60% - \\\u003C90% (high-risk grey zone)\n\nExclusion Criteria:\n\n* Presence of high-risk varices (HRV) (i.e. moderate to large oesophageal varices \\[OV\\] or OV with red wale sign) found in OGD\n* Current use of non-selective beta-blocker (NSBB) or any use of NSBB within 6 months before\n\n  * Use of selective beta blocker, such as atenolol or metoprolol, is not excluded\n  * Selective beta-blocker will be switched to carvedilol in NSBB arm, and will be kept unchanged in conventional arm if there is clinical need for the selective beta-blocker\n* Contraindication to NSBB (e.g. Type II\u002FIII heart block or baseline bradycardia \\\u003C60\u002Fminute, hypotension with systolic blood pressure (SBP) \\\u003C100 mmHg, asthma, poorly controlled chronic obstructive pulmonary disease, and peripheral vascular disease)\n* Current use of nitrated drugs or any use of nitrated drugs within 6 months before\n\n  o Use of sublingual nitrate, such as glyceryl trinitrate, is not excluded\n* Contraindication to OGD (e.g. Intestinal perforation or obstruction)\n* Current or history of decompensated liver cirrhosis (i.e. Child's C cirrhosis, prior decompensating events such as ascites, variceal bleeding, hepatic encephalopathy and hepatorenal syndrome)\n\n  o Child's B cirrhosis without decompensating events is not excluded\n* Current or history of hepatocellular carcinoma (HCC)\n* Current or history of portal vein thrombosis\n* Transjugular intrahepatic portosystemic shunt (TIPS)\n* Liver transplantation\n* Serious medical illness with limited life expectancy of less than 6 months\n* Pregnancy\n* Unable to obtain or refusal of informed consent from patient",{"count":122,"type":20},474,"INTERVENTIONAL",[125],"PHASE4","The goal of this randomised controlled trial is to evaluate the effect of carvedilol (a non-selective beta-blocker) in patients with compensated advanced chronic liver disease under clinically significant portal hypertension or the grey zone of Baveno VII criteria.\n\nThe main question it aims to answer is:\n\nDoes carvedilol reduce hepatic decompensation and mortality in these patients despite the absence of varices needing treatment.\n\nResearchers will compare carvedilol to no carvedilol to see if carvedilol can prevent hepatic decompensation and mortality.\n\nParticipants will either take carvedilol or not taking carvedilol for 5 years with regular clinic visit for checkups and investigations, including blood tests, ultrasonography of the liver, upper gastrointestinal endoscopy, transient elastography.",[51,128,24],"Hepatic Decompensation",[130,131,132,133],"compensated advanced chronic liver disease","non-selective beta-blocker","Baveno VII","hepatic decompensation","2025-06-17",{"date":136,"type":29},"2025-06-22",{"date":138,"type":29},"2024-07-17",{"date":140,"type":20},"2031-07-30",{"name":112,"class":36},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":123,"phases":152,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":37},"100549494","phase-3-zinc-supplementation-to-improve-prognosis-in-patients-with-compensated-advanced-chronic-liver-disease-100549494","NCT06434753","Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.","Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease: A Multicenter, Randomized, Double-blind, Placebo Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients of both sexes with diagnosed compensated advanced chronic liver disease (cACLD) determined by hepatic stiffness on transient elastography \\>15 kPa.\n* Age between 18 and 80 years, inclusive.\n* Absence of prior or current decompensation.\n* For women of childbearing age, a possible pregnancy will be ruled out by a pregnancy test prior to the start of the study. Following the test, the woman must use an effective contraceptive method during sexual intercourse (see Appendix I) in the days leading up to the start of treatment, and continue to use it throughout the treatment period, as well as for several days after its completion.\n* Signing of informed consent.\n\nExclusion Criteria:\n\n* History or current presence of hepatocellular carcinoma.\n* Concomitant systemic disease with a short-term poor prognosis.\n* Pregnancy, breastfeeding, or refusal to use contraceptive measures during participation in the study.\n* Patients with compensated advanced chronic liver disease (cACLD) due to hepatitis B virus (HBV) under antiviral treatment, and those with cACLD due to hepatitis C virus (HCV) cured with antiviral treatment.","80 Years",{"count":151,"type":20},300,[153],"PHASE3","Zinc homeostasis could play a role in advanced chronic liver disease (cACLD) and its supplementation has been linked with improvement in liver function, decrease of hepatic complications and reduction in hepatocellular carcinoma (HCC) incidence. cACLD encompasses a heterogeneous group of patients with a variable risk of clinically significant portal hypertension (CSPH) and clinical events. The ANTICIPATE model is a validated model for stratifying these risks. Our aim is to demonstrate that the administration of zinc can reduce the rate and risk of presenting clinical events (first decompensation, HCC, death and liver transplantation). This study protocol describes an ongoing phase III, national, multicentre, randomized, double-blind clinical trial that will enroll 300 patients to receive either the trial treatment (zinc acexamate) or placebo. An inclusion period of 42 months is planned, with a minimal duration of follow up of 2 years. Our principal hypothesis is that zinc could modify the natural history of cACLD patients, with an overall improvement in prognosis",[24,51,79],"2024-06-03",{"date":158,"type":29},"2024-06-04",{"date":160,"type":29},"2022-10-02",{"date":162,"type":20},"2026-03-02",{"name":164,"class":36},"Hospital Universitari Vall d'Hebron Research Institute"]